# TAYSHA GENE THERAPIES INC (TSHA)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/TSHA/

- Reporting holders: 3
- Reported value: $223.3K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Williams & Novak Wealth Management, LLC](https://holderbook.com/funds/1998419-williams-novak-wealth-management-llc/) | $219.2K | 45,000 | 0.1% | 12 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $3.8K | 786 | 0.0% | 4 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $365 | 75 | 0.0% | 5 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $223.3K |
| Q2 2026 | 210 | $2.2B |
| Q1 2026 | 193 | $1.2B |
| Q4 2025 | 196 | $1.5B |
| Q3 2025 | 154 | $869.5M |
| Q2 2025 | 150 | $597.2M |
| Q1 2025 | 128 | $232.2M |
| Q4 2024 | 130 | $290.0M |
| Q3 2024 | 117 | $321.7M |
| Q2 2024 | 107 | $361.2M |
| Q1 2024 | 110 | $433.0M |
| Q4 2023 | 87 | $231.1M |